Clinical trial · Interventional
Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Evaluation of HCC Response to Systemic Therapy With Quantitative MRI
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The incidence of hepatocellular carcinoma (HCC) has recently increased in the United States. Although imaging plays a major role in HCC screening and staging, the possibility of predicting HCC tumor grade, aggressiveness, angiogenesis and hypoxia with imaging are unmet needs. In addition, new antiangiogenic drugs now available to treat advanced HCC necessitate the use of new imaging criteria beyond size. The investigators would like to develop and validate non-invasive magnetic resonance imaging (MRI) methods based on advanced diffusion-weighted imaging (DWI), MR Elastography, BOLD (blood oxygen level dependent) MRI and perfusion-weighted imaging (PWI, using gadolinium contrast) to be used as non-invasive markers of major histopathologic features of HCC, and to predict and assess early response of HCC to systemic therapy. The investigators also would like to develop quality control tools to improve the quality and decrease variability of quantitative MRI metrics. These techniques combined could represent non-invasive correlates of histologic findings in HCC, could enable individualized therapy, and provide prognosis in patients with HCC.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Imaging | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Magnetic Resonance Imaging
- description
- dynamic contrast-enhanced MRI measuring arterial and portal flow
- interventionNames
- Device: Magnetic Resonance Imaging
- type
- NO_INTERVENTION
- label
- Healthy Controls
Primary outcomes (11)
- measure
- SubStudy 1: Apparent Diffusion Coefficient (ADC)
- timeFrame
- Day 1
- description
- Tumor diffusion (apparent diffusion coefficient) measured with diffusion-weighted imaging sequence
- measure
- SubStudy 1: Total Tumor Perfusion (Ft)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Study group * Patients diagnosed with HCC, who will undergo resection or transplantation within 6 months, as part of routine clinical care and patients diagnosed with unresectable HCC * 18 years of age and older * Patient is able to give informed consent for this study Control group * Healthy volunteers 18 years of age and older * Subject is able to give informed consent for this study Exclusion Criteria: * Age less than 18 years * Unable or unwilling to give informed consent * Contra-indications to MRI: 1. Electrical implants such as cardiac pacemakers or perfusion pumps 2. Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants 3. Ferromagnetic objects such as jewelry or metal clips in clothing 4. Pregnant subjects 5. Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions
References
Publications (0)
Data not yet available